Unassociated Document

® (NASDAQ: STAA) Cataract IOLs Refractive ICLs Benchmark One-on- One Investor Conference May 12, 2011

FORWARD -LOOKING STATEMENTS All statements in this presentation that are not statements of historical fact are forward -looking statements, including any projections of earnings, revenue, profit margin, cash or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements regarding expectations for success of the ICL or other products in U.S. or international markets, any statements concerning proposed new products and government approval of new products, services or developments, any statements regarding future economic conditions or performance, the size of market opportunities statements of belief and any statements of assumptions underlying any of the foregoing . These statements are based on expectations and assumptions as of the date of this presentation and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward -looking statements . The risks and uncertainties include our limited capital resources and limited access to financing, the broad discretion of the FDA and regulators in the European Community in approving any medical device and the inherent uncertainty that new devices will be approved, the likelihood of administrative delays, the need in certain future FDA submissions to satisfy additional and potentially costly requirements such as third party audits, the negative effect of the global recession on sales of products, especially products such as the ICL used in non-reimbursed elective procedures, the challenge of managing our foreign subsidiaries, the risk that sales of our newly introduced products may not restore profitability to our U.S. IOL product line, the risk that research and development efforts for planned products will not be successful, the willingness of surgeons and patients to adopt a new product and procedure, and the potential effect of negative publicity about LASIK on the demand for refractive surgery in general in the U.S., and the other factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 2, 2011. STAAR assumes no obligation to update its forward -looking statements to reflect future events or actual outcomes and does not intend to do so. Information for the first four months of 2011 is preliminary and not ® necessarily indicative of final second quarter results.

STAAR Investment Considerations Two Large Market Opportunities Two Differentiated Product Lines Double Digit Revenue Growth Profitable/Expanding Gross Margins New Technology Introductions/Approvals Strong Product Pipeline No Debt/Strong Balance Sheet ®

Intraocular Lens Focus Lenses Placed within the Eye Cataract Lens Refractive Lens Replaces natural Sits in front of natural crystalline lens crystalline lens Cataract IOL Refractive ICL™ ®

Surgical Refractive Correction Market Up to 1.5 billion nearsighted people worldwide 160 million contact lens wearers 5.1 M Annual Refractive procedures WW by 2015 7.1 % Annual Growth LASIK Market challenged by economy, technology limitations & negative media coverage Source: The Global Refractive Surgery Market by Market Scope December 2010 ®

Visian ICL ® Implantable Collamer Lens better known as “the Implantable Contact Lens” Made from a proprietary material called Collamer® Corrects myopia (nearsightedness) inability to see far distance Toric ICL version corrects both myopia and astigmatism Premium product with premium results ®

Visian ICL Competitive Landscape STAAR is the market leader in this segment >65% Unit Market Share Other players (Anterior Phakic IOL): Ophtec <30% Share Abbott has marketed as distributor with little success Novartis ~5% Share CE Mark Approval in August 2008 Very little success in Europe LASIK is the Real Competition ®

ICL vs. LASIK Small micro incision Incision over 1 inch-long Adds a lens into the eye Burns material away Permanent but removable Cannot be reversed Future options preserved May reduce future options Provides UV protection No UV protection No induced dry eye Potential dry eye induced 99% satisfied after five Varied percent of years with ICL enhancements ®

Superior Data for Young Adults in the Military with Low Myopia “Weapons Grade Vision” UCVA ICL ICL LASIK Fort Fort Lackland Bragg* Hood* Air Force** 20/10 or better 9% 4% 20/15 or better 81% 78% 50% 20/20 or better 98% 100% 93% * Eyes with pre-op cylinder of 1D or less. ** Dr. Chaz Riley, USAF, Ocular Surgery News, September 25, 2010, 838 eyes with wavefront -optimized LASIK and PRK. ®

VISIAN ICL GROWTH DYNAMICS 24.48% growth first four months of 2011 Next Generation Products Recently Approved V4b with Expanded Treatment Ranges V4c eliminating the need for an iridotomy New Visian ICL DTC Campaign Trials Potential New Approvals in U.S. and Japan Visian ICL gaining market share globally ®

New Visian V4b ICL Introduced in 23 of 25 CE markets New ranges alone accounted for 8% growth Q1 Expands treatment range on both Visian ICL (myopia) and HICL (hyperopia) Can treat virtually any refractive error Can be used as LASIK enhancement New Visian Hyperopic Toric ICL ®

New Visian V4c ICL Proprietary aqueous port in center of ICL Restores natural flow within the eye Eliminates the need for iridotomy Makes procedure much more convenient for the patient and surgeon (LASIK -like) Makes economics better for the surgeon Rollout in Europe the Second Half of 2011 ®

Visian V4c ICL Clinical Trials First Phase study in 2008 (Dr. Shimizu in Japan) 6 patients implanted with standard ICL in one eye and modified ICL in fellow eye. Second Phase study in 2010 (Dr. Shimizu) 19 patients – repeated same protocol Dr. Shimizu has continued to use

Visian ICL Product Pipeline Product R D CE Japan U.S. Toric ICL √ √ √ 2011 2011 V4b Expanded Range √ √ √ NP NP Lower myopes and toric hyperopic V4c √ √ √ E E Eliminates need for PI V5 E E 2012 2012 2013 Preloaded, enhanced safety design V6 E E Multifocal, MF Toric, forgiving design E= In the planning stage. ®

Visian ICL DTC Testing Movie Theater: STAAR Campaign Pre-movie ads, shown before all movies for 4 weeks In-lobby promotions – consumer leaflets – surgeon and/or visianinfo Evaluating data currently for next test market Cable TV: Co-op Campaign with Local Surgeon Network TV Co-op Campaign with Local Surgeon ®

DTC Working in Korea Moved Market Share from 5% to 12% in 2 Years 30 Second Radio Ads Subway Signage Bus Wraps ®

Visian ICL Revenue Gains Increase of 24.48% through 4 Months 2011 $7.0 $6.0 $5.0 ons $4.0 Milli $3.0 $2.0 $1.0 $0.0 Q305 Q405 Q106 Q206 Q306 Q406 Q107 Q207 Q307 Q407 Q108 Q208 Q308 Q408 Q109 Q209 Q309 Q409 Q110 Q210 Q310 Q410 Q111 •10% ICL market penetration equals $200M at 85% to 90% GM ®

Worldwide Cataract Market “Large and Growing” $3.4 billion Worldwide Cataract IOL market in 2015 8.1% CAGR U.S. Market is $1 billion in 2015 6.5% CAGR Driven by innovation / improved outcomes / aging population Source: The Global IOL Market by Market Scope June 2010 ®

Cataract IOL Competitive Landscape is Tough 18.9 million global IOLs Implanted in 2010 The Big Three Global IOL share leaders Alcon (Novartis) 53% AMO (Abbott) 16% B&L (Private) 10% STAAR goal: the fastest growing in target markets 7% share in Japan, 3% share in U.S., target markets Other players: Hoya, Kowa, Lenstec, Rayner, and Zeiss ® Source: The Global IOL Market by Market Scope June 2010

STAAR Cataract IOLs Preloaded Proprietary IOLs nanoFLEX Family of IOLs •Acrylic •Silicone Silicone Toric Plate Collamer nanoFLEX (Premium Channel) Aspheric (NTIOL) Strategy: Move to Premium IOLs • Aspheric • Toric Collamer • Less spectacle dependent •All Preloaded ®

Unique Collamer ® Material Proprietary hydrophilic material produces superior quality of vision 40% water content produces: Reduced glare or halo effect Free from glistenings Patent protection until 2014/mfg know-how Preliminary data demonstrates “accommodation” potential ®

CAST with nanoFLEX ®IOL “Collamer Accommodating Study Team” Clinical observations: Collamer provides some accommodation or better visual results Inherent property of the material?? Collamer Accommodating Study Team Eight leading ophthalmic surgeons All patients tested with same reading tools to measure near and intermediate vision ®

CAST Findings Distance Vision: All cataract patients see very well at far distance Near Vision: Usually need some reading glasses nanoFLEX SUPERIOR to all Standard IOLs Intermediate Vision: Usually need glasses for laptop nanoFLEX SUPERIOR to ALL IOLs, both Standard and Premium ®

Global Premium IOL Channel 536k procedures grow to 3.3M in 2020 $365M market grow to $1.3B by 2016 “Rapidly increasing presbyopic segment” U.S. market will be 41% of procedures in 2020 Provides good near, intermediate and distance vision results Surgeons and patients motivated Source: The Global Market for Presbyopia-Correcting Surgery ® by Market Scope March 2011

nanoFLEX CE Mark Approval Approval received in late April Will begin rollout to key European markets beginning in June Believe that the nanoFLEX Toric IOL will follow later this year to CE Markets Upside to 2011 expectations and 2012 full year (the nanoFLEX Family) ®

STAAR IOL Product Pipeline Product R D CE Japan U.S. Preloaded Silicone √ √ √ √ 2011 Preloaded 1P Acrylic √ √ 2011 √ NP nanoFLEX IOL √ √ √ ?? √ nanoFLEX Toric √ E 2011 ?? 2011 nanoFLEX II E E 2012 ?? 2012* *Depends on label claim pursued. Could be 2013. ® E= In the planning stage.

2011 Q1 Results Comparison to Q1 2010 ($000’s) Q1 2011 Q1 2010 Improvement Revenue/CORE $14,849 $13,778 +8%/+10% Gross Profit Dollars $9,629 $8,829 +9% Gross Profit Margin 64.8% 64.1% +70bps Operating Expenses $9,421 $8,752 +8% Operating Income $208 $76 +173% Inc./Loss from Cont’d Ops $300 ($636) +$936 *Q1 2010 Net Income reported as $3.5M based upon $4.1M on net gain of divestiture . ®

2011 Key Metric Report Card Q1 Q2 Q3 Q4 2010 Double Digit Revenue Growth* Grow ICL Sales by 25%* Continuous Expansion of GM %, End year at 66% Profitable in 3 of 4 quarters and for the full year *Through 4 months 2011: Revenue +10% and ICLs +24.48% ®

STAAR Balance Sheet Profitable & Generating Cash/$10.4M end of Q1 Company Basically Debt Free Only a working line of credit in Japan $128M in NOLs (Worth $1 a share) 35 million shares of common stock outstanding 1.4 million warrants at approximately $4 ®

STAAR Near Term Catalysts European Launch of New ICL & IOL Products Visian ICL V4b and V4c nanoFLEX IOL Visian ICL growth in Japan (2010 approval) FDA and PMDA Approval of Visian Toric ICL CAST II clinical results for Cataract IOLs ®

® (NASDAQ: STAA) Cataract IOLs Refractive ICLs Benchmark One-on- One Investor Conference May 12, 2011